Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Objections To Pharma Mergers Could Go Unchallenged Following Wilson’s Resignation

Executive Summary

The commission no longer has a voice opposing aggressive antitrust enforcement actions and President Biden's replacement may be more receptive to the stance of the three current Democratic commissioners. Amgen’s proposed acquisition of Horizon is facing FTC scrutiny.

You may also be interested in...

Reading The FTC Tea Leaves: Investors Await Insights For M&A

Pfizer and Amgen both have large M&A deals under regulatory review, and investors will be eager to hear updates on how those transactions are progressing during Q2 reporting.

FTC’s Khan Addresses PBMs, Amgen-Horizon Merger, At Contentious Congressional Hearing

Republican members of the House Judiciary Committee question FTC policies under Khan’s leadership, including its challenge of the Amgen-Horizon and Illumina-Grail mergers, as well as a proposal to require more information in pre-notification submissions. ‘You’re a bully,’ Representative Issa tells her.

FTC's GOP Seat Nominees Formerly Clerked For Justice Thomas, Led Conservative Policy Group

Amid period of 3-0 decisions by commission, President Biden nominates two state solicitor generals for vacant FTC seats, both reserved for GOP appointments. Virginia’s Andrew Ferguson previously clerked for Justice Thomas and was Senate GOP leader McConnell’s chief counsel; Utah’s Melissa Holyoak led a conservative advocacy group focused on fighting class action lawsuits and aggressive regulation.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts